Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

24.6%

14 terminated/withdrawn out of 57 trials

Success Rate

72.5%

-14.0% vs industry average

Late-Stage Pipeline

21%

12 trials in Phase 3/4

Results Transparency

111%

41 of 37 completed trials have results

Key Signals

2 recruiting41 with results10 terminated4 withdrawn

Enrollment Performance

Analytics

Phase 2
26(48.1%)
Phase 1
12(22.2%)
Phase 3
10(18.5%)
N/A
4(7.4%)
Phase 4
2(3.7%)
54Total
Phase 2(26)
Phase 1(12)
Phase 3(10)
N/A(4)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (57)

Showing 20 of 57 trials
NCT05835466Phase 2Recruiting

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Role: collaborator

NCT07395232Phase 3Recruiting

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

Role: lead

NCT07453888Phase 3Not Yet Recruiting

Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Role: lead

NCT07519902Phase 3Not Yet Recruiting

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

Role: lead

NCT07503886Phase 2Not Yet Recruiting

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

Role: lead

NCT05254990Phase 3Terminated

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Role: lead

NCT06244316Phase 2Completed

A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

Role: lead

NCT05758753Not ApplicableSuspended

QST for Corneal Nerve Function

Role: collaborator

NCT04628481Phase 2Terminated

A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function

Role: lead

NCT05552261Completed

DEFENDO Long Term Follow-up Study in Stage 1 NK Patients

Role: lead

NCT05136170Phase 3Completed

Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

Role: lead

NCT06411132Terminated

Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye

Role: lead

NCT04485546Phase 4Completed

Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis

Role: lead

NCT05496868Phase 2Completed

Add-on Reparixin in Adult Patients With ARDS

Role: lead

NCT04899271Phase 2Terminated

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

Role: lead

NCT04627571Completed

Corneal Nerves After Treatment With Cenegermin

Role: collaborator

NCT02510235Not ApplicableCompleted

Tolerability, Safety and Efficacy of Lubricin vs Sodium Hyaluronate Eye Drops in Subjects With Moderate Dry Eye

Role: lead

NCT05368402Phase 2Terminated

Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.

Role: lead

NCT03031470Phase 2Terminated

Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation

Role: lead

NCT04802967Phase 1Completed

A Study on Ketoprofen Lysine Salt (KLS) + Gabapentin (GABA) vs KLS to Investigate Their Pharmacodynamic in Healthy Males

Role: lead